美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

罗氏控股

39.27

-0.2400-0.61%

盘后：39.23-0.0400-0.10%16:01 EDT

成交量：63.23万

成交额：2,489.14万

市值：2,542.35亿

市盈率：25.32

高：39.48

开：39.31

低：39.17

收：39.51

数据加载中...

总览公司新闻公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻

罗氏(RHHBY.US)注射用维泊妥珠单抗新适应症国内上市申请获受理

罗氏(RHHBY.US)Susvimo用于治疗糖尿病视网膜病变获FDA批准

罗氏(RHHBY.US)宣布肝癌III期临床研究TALENTACE达到主要研究终点

罗氏(RHHBY.US)公布“帕妥珠单抗”乳腺癌Ⅲ期研究最新数据

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/RHHBY?region=SGP"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"罗氏控股","latestPrice":39.27,"timestamp":1748462400000,"preClose":39.51,"halted":0,"volume":632332,"hourTrading":{"tag":"盘后","latestPrice":39.23,"preClose":39.27,"latestTime":"16:01 EDT","volume":13156,"amount":516280.12,"timestamp":1748462510629},"delay":15,"floatShares":6374000000,"shares":6474029800,"eps":1.550894,"marketStatus":"未开盘","change":-0.24,"latestTime":"05-28 16:00:00 EDT 延时","open":39.3099,"high":39.48,"low":39.17,"amount":24891408.4482001,"amplitude":0.007846,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1748505600000},"marketStatusCode":0,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":39.51,"volumeRatio":0.519571},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6374000000,"roa":"12.75%","roe":"26.47%","lyrEps":2.136203,"volumeRatio":0.519571,"shares":6474029800,"dividePrice":1.34,"high":39.48,"amplitude":0.007846,"preClose":39.51,"low":39.17,"week52Low":31.19,"pbRate":"6.65","psRate":"3.39","week52High":44.31,"institutionHeld":0,"latestPrice":39.27,"eps":1.550894,"divideRate":0.034123,"volume":632332,"delay":15,"ttmEps":1.550894,"open":39.3099,"prevYearClose":34.88,"prevWeekClose":39.67,"prevMonthClose":40.77,"prevQuarterClose":41.15,"fiveDayClose":39.71,"twentyDayClose":40.66,"sixtyDayClose":41.83},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RHHBY\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538357447","title":"罗氏(RHHBY.US)注射用维泊妥珠单抗新适应症国内上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2538357447","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538357447?lang=zh_cn&edition=fundamental","pubTime":"2025-05-28 15:39","pubTimestamp":1748417975,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月28日，CDE官网显示，罗氏注射用维泊妥珠单抗新适应症上市申请获受理。今年4月，罗氏在一季度报中披露，2025年将递交维泊妥珠单抗联合莫妥珠单抗二线以上DLBCL适应症的上市申请。2023年1月，维泊妥珠单抗进入中国市场，适应症为：1）联合利妥昔单抗、环磷酰胺、多柔比星和泼尼松适用于治疗既往未经治疗的DLBCL成人患者；2）联合苯达莫司汀和利妥昔单抗用于不适合接受造血干细胞移植的R/RDLBCL成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1298542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"罗氏(RHHBY.US)注射用维泊妥珠单抗新适应症国内上市申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","RHHBY","BK4007"],"gpt_icon":0},{"id":"2537732976","title":"罗氏(RHHBY.US)Susvimo用于治疗糖尿病视网膜病变获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2537732976","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537732976?lang=zh_cn&edition=fundamental","pubTime":"2025-05-23 08:37","pubTimestamp":1747960633,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，罗氏今日宣布，美国FDA批准Susvimo100 mg/mL用于治疗糖尿病视网膜病变。根据新闻稿，Susvimo是首个经FDA批准可持续释放、并在每9个月仅需一次补充给药的DR治疗方案，已被证实可维持患者的视力。此次FDA的批准主要基于Pavilion临床3期研究的一年期积极结果。此外，Susvimo治疗组在一年内无一例患者需要额外辅助治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1296678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"罗氏(RHHBY.US)Susvimo用于治疗糖尿病视网膜病变获FDA批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","RHHBY","BK4007"],"gpt_icon":0},{"id":"2537356603","title":"罗氏(RHHBY.US)宣布肝癌III期临床研究TALENTACE达到主要研究终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2537356603","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537356603?lang=zh_cn&edition=fundamental","pubTime":"2025-05-21 14:22","pubTimestamp":1747808533,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月21日，罗氏宣布III期TALENTACE研究达到主要研究终点，该研究评估了阿替利珠单抗、贝伐珠单抗和按需经动脉化疗栓塞术在未接受过既往全身系统治疗的不可切除肝细胞癌患者中的疗效和安全性。TALENTACE研究开创性地探索了免疫检查点抑制剂阿替利珠单抗联合抗血管生成靶向治疗贝伐珠单抗与按需TACE同期联合治疗的协同效应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1295741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RHHBY","03165","BK4134","III","BK4007"],"gpt_icon":0},{"id":"2535779040","title":"罗氏(RHHBY.US)公布“帕妥珠单抗”乳腺癌Ⅲ期研究最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2535779040","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535779040?lang=zh_cn&edition=fundamental","pubTime":"2025-05-13 15:38","pubTimestamp":1747121922,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月13日，罗氏公布III期APHINITY研究的最终总生存期结果，该研究针对HER2阳性早期乳腺癌患者。APHINITY是一项全球性 III 期、随机、双盲、安慰剂对照、双组研究，旨在评估帕妥珠单抗联合赫赛汀联合化疗作为术后(辅助)治疗的疗效和安全性，并与赫赛汀联合化疗进行比较。包括心脏安全性在内的安全性与先前研究一致，未发现新的或意外的安全信号。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1292461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","BK4007","RHHBY"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2025-07-24","symbol":"RHHBY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1753344000000,"name":null,"time":"盘前","dateTimestamp":1753329600000,"actualEps":null},{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null},{"market":"US","date":"2024-02-01","symbol":"RHHBY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-02","recordDate":"2016-03-04","paymentDate":"2016-04-22","value":0.837655,"currency":"USD"},{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.125,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.75,"analysts":8,"updateTime":1745899200000}}}